The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Covid-19 Hit Sends National Express Lower

Thu, 13th Aug 2020 11:02

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

Just Eat Takeaway, up 2.6%. The online food delivery platform was counting gains after it posted positive interim results on Wednesday. The stock closed up 3.7% on Wednesday.

----------

FTSE 100 - LOSERS

----------

Phoenix Group, down 3.7%, Legal & General, down 1.8%, Aviva, down 2.3%. GlaxoSmithKline, down 2.3%. Royal Dutch Shell A, down 2.2%, Shell B, down 2.1%. The stocks listed in this section all went ex-dividend on Thursday, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - WINNERS

----------

Watches of Switzerland, up 16%. The luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company. For the financial year ended April 26, revenue was up 6% to GBP819.3 million from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million. For financial 2021, Watches of Switzerland expects revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US. The company re-opened the majority of its stores during the first quarter, with July registering 7.4% growth in sales versus a year ago, the first full month when the majority of the network was re-opened. June sales were up 0.3%, while May registered a 83% drop.

----------

FTSE 250 - LOSERS

----------

National Express, down 12%. The transport company swung to a bruising loss during a first-half that was focused on limiting the damage from Covid-19, which has battered the public transport sector. The bus, coach and train operator swung to a GBP122.2 million pretax loss in the six months to June 30 from a GBP88.4 million profit a year earlier. Revenue dropped 23% to GBP1.03 billion from GBP1.34 billion. There was no interim dividend, as previously guided, following a 5.16p payout a year ago. There is also no annual profit guidance, due to Covid-19 uncertainty.

----------

Renishaw, down 11%. The British engineering company warned of the continuation of "very challenging" macroeconomic conditions due to the Covid-19 pandemic. For the financial year that ended June 30 pretax profit fell to GBP3.2 million down 97% from GBP109.9 million recorded a year ago. The sharp drop was attributed to restructuring costs, losses in value of financial instruments and financial expenses. Annual revenue fell 11% to GBP510.2 million from GBP574.0 million. Metrology division revenue was lower by 11% at GBP475.2 million, largely as a result of trade tensions between the US and China, weaker demand in the machine tool sector, and the impact of the pandemic. Healthcare revenue decreased by 15% to GBP35.0 million, with Covid-19 causing delays in orders, shipments, installations and postponements of elective surgery. It stated that a final dividend will not be declared in 2020.

----------

TUI, down 4.2%. The Anglo-German holiday firm offered a bleak picture to investors after third-quarter results highlighted how severely hit the travel sector was due to Covid-19 lockdown. Tui reported a pretax loss of EUR1.46 billion for the period ended June 30, swinging from a EUR60 million profit a year before, as revenue plunged 98% to EUR75 million. Third-quarter underlying loss before interest and tax amounted to EUR1.1 billion due to suspension of operations for the majority part of the quarter, resulting in impairment charges and costs arising from ineffective hedging contracts. For the nine months to June-end, the company's revenue fell 41% To EUR6.71 billion, resulting in a sharply widened pretax loss of EUR2.34 billion from a EUR323.3 million loss a year ago. The nine-month underlying Ebit loss amounted to EUR2.0 billion, an increase of EUR1.8 billion versus a year prior, reflected underlying costs of EUR1.3 billion from business suspension since March, impairments triggered totalling EUR410 million, and net costs from ineffective hedges amounting to EUR189 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

ASOS, up 3.5%. The online fashion retailer was upgraded to Hold from Sell by Liberum. ASOS on Wednesday said its annual sales and profit are likely to be "significantly ahead of market expectations" as customer returns did not increase as fast as expected.

----------

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.